Sajjad Raza1, Syed T Hussain1, Jeevanantham Rajeswaran2, Asif Ansari3, Matteo Trezzi1, Amr Arafat1, James Witten4, Kirthi Ravichandren1, Haris Riaz5, Hoda Javadikasgari1, Sunil Panwar1, Sevag Demirjian3, Nabin K Shrestha6, Thomas G Fraser6, José L Navia1, Bruce W Lytle1, Eugene H Blackstone7, Gösta B Pettersson8. 1. Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. 2. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. 3. Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. 4. Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio. 5. Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio. 6. Department of Infectious Disease, Medicine Institute, Cleveland Clinic, Cleveland, Ohio. 7. Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. 8. Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: petterg@ccf.org.
Abstract
OBJECTIVES: To determine the value of surgery for infective endocarditis (IE) in patients on hemodialysis by comparing the nature and invasiveness of endocarditis in hemodialysis and nonhemodialysis patients and their hospital and long-term outcomes, and identifying risk factors for time-related mortality after surgery. METHODS: From January 1997 to January 2013, 144 patients on chronic hemodialysis and 1233 nonhemodialysis patients underwent valve surgery for IE at our institution. Propensity matching identified 99 well-matched hemodialysis and nonhemodialysis patient pairs for comparison of outcomes. RESULTS: Staphylococcus aureus infection was more common in hemodialysis patients than in nonhemodialysis patients (42% vs 21%; P < .0001), but invasive disease was similar in the 2 groups (47%; P = .3). Hospital mortality was 13% and 5-year survival was 20% for hemodialysis patients, 20% below that expected in a general hemodialysis population but 15% above that of hemodialysis patients treated nonsurgically for IE. For matched patients, hospital mortality was 13% for hemodialysis patients versus 5.1% for nonhemodialysis patients (P = .05), and survival at 1 and 5 years was 56% versus 83% and 24% versus 59%, respectively (P < .004). Use of an arteriovenous graft for dialysis access (P = .01) and preoperative placement of a pacemaker (P < .0001) were risk factors for late mortality in hemodialysis patients. For matched patients, freedom from reoperation was similar in the hemodialysis and nonhemodialysis groups (P > .9). CONCLUSIONS: Intermediate-term survival after surgery for IE in hemodialysis patients is substantially worse than that in nonhemodialysis patients, but only slightly worse than that in the general hemodialysis population and substantially better than that in hemodialysis patients with IE treated nonsurgically, supporting continued surgical intervention for IE.
OBJECTIVES: To determine the value of surgery for infective endocarditis (IE) in patients on hemodialysis by comparing the nature and invasiveness of endocarditis in hemodialysis and nonhemodialysis patients and their hospital and long-term outcomes, and identifying risk factors for time-related mortality after surgery. METHODS: From January 1997 to January 2013, 144 patients on chronic hemodialysis and 1233 nonhemodialysis patients underwent valve surgery for IE at our institution. Propensity matching identified 99 well-matched hemodialysis and nonhemodialysis patient pairs for comparison of outcomes. RESULTS:Staphylococcus aureus infection was more common in hemodialysis patients than in nonhemodialysis patients (42% vs 21%; P < .0001), but invasive disease was similar in the 2 groups (47%; P = .3). Hospital mortality was 13% and 5-year survival was 20% for hemodialysis patients, 20% below that expected in a general hemodialysis population but 15% above that of hemodialysis patients treated nonsurgically for IE. For matched patients, hospital mortality was 13% for hemodialysis patients versus 5.1% for nonhemodialysis patients (P = .05), and survival at 1 and 5 years was 56% versus 83% and 24% versus 59%, respectively (P < .004). Use of an arteriovenous graft for dialysis access (P = .01) and preoperative placement of a pacemaker (P < .0001) were risk factors for late mortality in hemodialysis patients. For matched patients, freedom from reoperation was similar in the hemodialysis and nonhemodialysis groups (P > .9). CONCLUSIONS: Intermediate-term survival after surgery for IE in hemodialysis patients is substantially worse than that in nonhemodialysis patients, but only slightly worse than that in the general hemodialysis population and substantially better than that in hemodialysis patients with IE treated nonsurgically, supporting continued surgical intervention for IE.
Authors: Ryan A Moore; James C Witten; Ashley M Lowry; Nabin K Shrestha; Eugene H Blackstone; Shinya Unai; Gösta B Pettersson; Per Wierup Journal: J Thorac Cardiovasc Surg Date: 2022-04-05 Impact factor: 6.439
Authors: Dharmenaan Palamuthusingam; Arun Nadarajah; Elaine M Pascoe; Jonathan Craig; David W Johnson; Carmel M Hawley; Magid Fahim Journal: PLoS One Date: 2020-06-26 Impact factor: 3.240
Authors: John A Woller Iii; Victoria L Walsh; Chad Robichaux; Vinod H Thourani; Jesse T Jacob Journal: Open Forum Infect Dis Date: 2018-10-20 Impact factor: 3.835
Authors: Mavish S Chaudry; Gunnar H Gislason; Anne-Lise Kamper; Marianne Rix; Anders Dahl; Lauge Østergaard; Emil L Fosbøl; Trine K Lauridsen; Louise B Oestergaard; Christian Hassager; Christian Torp-Pedersen; Niels E Bruun Journal: BMC Nephrol Date: 2018-09-03 Impact factor: 2.388